The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Further, in a recent phase I trial, lymphoma arising from piggyBac transfected CAR T cells has been reported in two of nine patients with relapsed or refractory B-cell malignancies who achieved complete remission after product infusion.”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0201-9 · Cited by 659
Micklethwaite, K. P., Gowrishankar, K., Gloss, B. S., Li, Z., Street, J. A., Moezzi, L., Mach, M. A., Sutrave, G., Clancy, L. E., Bishop, D. C., et al. (2021) · Blood · doi:10.1182/blood.2021010858 · Cited by 226
Self-citation
Research works printed but not linked: 22
- Cruz, 2013, Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study, Blood., 122, 2965, 10.1182/blood-2013-06-506741 · DOI
- Kochenderfer, 2013, Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation, Blood., 122, 4129, 10.1182/blood-2013-08-519413 · DOI
- Kebriaei, 2016, Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells, J Clin Invest., 126, 3363, 10.1172/JCI86721 · DOI
- Schuster, 2017, Chimeric antigen receptor T cells in refractory B-cell lymphomas, N Engl J Med., 377, 2545, 10.1056/NEJMoa1708566 · DOI
- Turtle, 2017, Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib, J Clin Oncol., 35, 3010, 10.1200/JCO.2017.72.8519 · DOI
- Lin, 2018, Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia, J Clin Oncol., 36, 3192, 10.1200/JCO.2018.79.0642 · DOI
- Dai, 2015, Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia, OncoImmunology., 4, e1027469, 10.1080/2162402X.2015.1027469 · DOI
- Brudno, 2016, Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease, J Clin Oncol., 34, 1112, 10.1200/JCO.2015.64.5929 · DOI
- Ramanayake, 2015, Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials, Cytotherapy., 17, 1251, 10.1016/j.jcyt.2015.05.013 · DOI
- Bishop, 2020, CAR T cell generation by piggyBac transposition from linear doggybone DNA vectors requires transposon DNA-flanking regions, Mol Ther Methods Clin Dev., 17, 359, 10.1016/j.omtm.2019.12.020 · DOI
- Bishop, 2018, PiggyBac-engineered T cells expressing CD19-specific CARs that lack IgG1 Fc spacers have potent activity against B-ALL xenografts, Mol Ther., 26, 1883, 10.1016/j.ymthe.2018.05.007 · DOI
- Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome, Blood., 124, 188, 10.1182/blood-2014-05-552729 · DOI · Paper page
- Hay, 2017, Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy, Blood., 130, 2295, 10.1182/blood-2017-06-793141 · DOI · Paper page
- Gust, 2017, Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells, Cancer Discov., 7, 1404, 10.1158/2159-8290.CD-17-0698 · DOI · Paper page
- Gregory, 2018, Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM), Blood., 132, 1012, 10.1182/blood-2018-99-111419 · DOI
- Srour, 2020, Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas, Blood., 135, 862, 10.1182/blood.2019002920 · DOI
- Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J Clin Invest., 118, 3143, 10.1172/JCI35798 · DOI · Paper page
- Galvan, 2009, Genome-wide mapping of PiggyBac transposon integrations in primary human T cells, J Immunother., 32, 837, 10.1097/CJI.0b013e3181b2914c · DOI
- Huang, 2010, Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells, Mol Ther., 18, 1803, 10.1038/mt.2010.141 · DOI
- Hamada, 2018, Integration mapping of piggyBac-mediated CD19 chimeric antigen receptor T Cells Analyzed by Novel Tagmentation-assisted PCR, EBioMedicine., 34, 18, 10.1016/j.ebiom.2018.07.008 · DOI
- Cheson, 2014, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol., 32, 3059, 10.1200/JCO.2013.54.8800 · DOI · Paper page
- Neelapu, 2018, Chimeric antigen receptor T-cell therapy - assessment and management of toxicities, Nat Rev Clin Oncol., 15, 47, 10.1038/nrclinonc.2017.148 · DOI · Paper page
Cited by
Sorted by citations
CAR T therapy beyond cancer: the evolution of a living drug
Baker, D. J., Arany, Z. P., Baur, J. A., Epstein, J. A., & June, C. H. (2023) · Nature · doi:10.1038/s41586-023-06243-w · Cited by 546
Hayden, P. J., Roddie, C., Bader, P., Basak, G. W., Bonig, H. B., Bonini, C., Chabannon, C., Ciceri, F., Corbacioglu, S., Ellard, R., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.003 · Cited by 486
From bench to bedside: the history and progress of CAR T cell therapy
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q. F., & He, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188049 · Cited by 526
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0084 · Cited by 321
“The analysis of the lymphoma samples showed an increase in the transgene copy numbers but with no integration in typical oncogenes (107, 108).”
BackgroundCAR-T cell manufacturing: Major process parameters and next-generation strategies
Ceja, M. A., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230903 · Cited by 349
“In a phase 1 clinical trial, two patients treated with allogeneic CD19 CAR-T cell products generated with the piggyBac transposon system developed CAR-T cell – derived lymphoma, resulting in one fatality (Bishop et al., 2021).”
Background
Metadata
- Authors
- Bishop, D. C., Clancy, L. E., Simms, R., Burgess, J., Mathew, G., Moezzi, L., Street, J. A., Sutrave, G., Atkins, E., McGuire, H. M., Gloss, B. S., Lee, K., Jiang, W., Maddock, K., McCaughan, G., Avdic, S., Antonenas, V., O’Brien, T. A., Shaw, P. J., Irving, D. O., Gottlieb, D. J., Blyth, E., & Micklethwaite, K. P.
- Affiliations
- The University of Sydney (AU)
- Westmead Institute for Medical Research (AU)
- Westmead Hospital (AU)
- NSW Health Pathology (AU)
- Children’s Cancer Institute, Sydney, NSW, Australia;
- University of Technology Sydney (AU)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-10-21
- Volume
- 138
- Issue
- 16
- Pages
- 1504-1509
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3160982226
- Cited by
- 177
- References
- 27
- Citations by year
- 2026: 20 · 2025: 35 · 2024: 45 · 2023: 31 · 2022: 29 · 2021: 17
- FWCI
- 11.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- David and Elaine Potter Foundation
- Ian Potter Foundation
- Cancer Australia (1047454)
- Cancer Institute NSW
- Cure Cancer Australia Foundation
- Medical Research Council
- National Health and Medical Research Council (1102172)
- Cancer Council NSW
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, piggyBac transposon, CD19, T-cell leukemia, B-cell acute lymphoblastic leukemia
- MeSH terms
- Adult, Aged, DNA Transposable Elements, Female, Humans, Lymphoma, Male, Middle Aged, Receptors, Antigen, T-Cell, Leukemia, B-Cell, Immunotherapy, Adoptive, Lymphoma, B-Cell, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
